12:00 AM
 | 
Feb 26, 2001
 |  BioCentury  |  Product Development

The Genentech way

Only a week after the human genome was completed, Genentech Inc. downplayed the importance of genomics at its investors day meeting in New York last week. Although genomics is one of DNA's areas of research, the company believes that biology, such as cell-based assays, will continue to be the primary tool for bringing molecules to market.

Moreover, DNA does not see genomics speeding the rate of drug development, although it does envision an increase in the number of products getting to market given the discovery of more targets.

Although the company has had increased...

Read the full 457 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >